Skip to content

Study · Animal study (in vivo) · mouse and rat · 1999

2 results

Pentadecapeptide BPC 157 attenuates gastric lesions induced by alloxan in rats and mice.

Petek M, Sikiric P, Anic T, Buljat G, Separovic J, Stancic-Rokotov D, Seiwerth S, Grabarevic Z, Rucman R, Mikus D, Zoricic I, Prkacin I and 8 more

Show all authors

Sebecic B, Ziger T, Coric V, Turkovic B, Aralica G, Rotkvic I, Mise S, Hahn V

Journal of physiology, Paris1 Dec 1999Cited by 6 (Europe PMC)

PMID10672996 (opens in a new tab)DOI10.1016/s0928-4257(99)00120-5 (opens in a new tab)PepBankPUB-10672996
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats given alloxan, BPC‑157 given together with alloxan significantly attenuated the appearance of gastric lesions.

    In plain wordsIn rats given the diabetes-inducing drug alloxan, BPC‑157 reduced stomach lesions.

    Peptide
    BPC-157
    Outcome
    DecreaseAlloxan-induced gastric lesions
    Study

    ratn: not reported in source

    alloxan-induced gastric lesions
    Comparator
    Alloxan control
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 µg or 10 ng/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    The application of the pentadecapeptide BPC 157 (10 microg or 10 ng x kg(-1) i.p. coadministered together with alloxan) would significantly attenuate these lesions' appearance.
    3 context sentences
    Summary · context
    A diabetogenic alloxan regimen produced lesions in all stomachs of treated animals, either rats (200 mg x kg(-1) s.c.) or mice (400 mg x kg(-1) i.p.).
    Summary · context
    This beneficial effect seems to be present in either rats or mice and in either of the tested intervals.
    Summary · context
    Importantly, the beneficial effect seems to be shared by both microgram and nanogram regimens.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice given alloxan, BPC‑157 given together with alloxan attenuated the appearance of gastric lesions.

    In plain wordsIn mice given the diabetes-inducing drug alloxan, BPC‑157 reduced stomach lesions.

    Peptide
    BPC-157
    Outcome
    DecreaseAlloxan-induced gastric lesions
    Study

    mousen: not reported in source

    alloxan-induced gastric lesions
    Comparator
    Alloxan control
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 µg or 10 ng/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    The application of the pentadecapeptide BPC 157 (10 microg or 10 ng x kg(-1) i.p. coadministered together with alloxan) would significantly attenuate these lesions' appearance.
    3 context sentences
    Summary · context
    A diabetogenic alloxan regimen produced lesions in all stomachs of treated animals, either rats (200 mg x kg(-1) s.c.) or mice (400 mg x kg(-1) i.p.).
    Summary · context
    This beneficial effect seems to be present in either rats or mice and in either of the tested intervals.
    Summary · context
    Importantly, the beneficial effect seems to be shared by both microgram and nanogram regimens.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.